Alnylam Pharmaceuticals
ALNY
143.82
-4.00
-2.71%
Alnylam Pharmaceuticals
US · ALNY
#627 by market cap
Listed 1970
143.82
-4.00
-2.71%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Rating change
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor FitzgeraldDow Jones · 2026/11/17
-
Company notice
Alnylam Pharmaceuticals | SCHEDULE 13G: OthersSEC · 2026/11/17
-
Company notice
Alnylam Pharmaceuticals | SCHEDULE 13G/A: OthersSEC · 2026/11/14
-
Rating change
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455Market Newswire · 2026/11/12
-
Rating change
Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $250Market Newswire · 2026/11/10
-
Rating change
Citi Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $250Market Newswire · 2026/11/9
-
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $293Market Newswire · 2026/11/20
-
Rating change
Cantor Fitzgerald Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $290Market Newswire · 2026/11/7
-
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $250Market Newswire · 2026/11/17
-
Company notice
Alnylam Pharmaceuticals | SCHEDULE 13G/A: OthersSEC · 2026/11/14
-
Rating change
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $410Market Newswire · 2026/11/10
-
Rating change
Wells Fargo Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $220Market Newswire · 2026/11/5
-
Rating change
Alnylam Pharmaceuticals Is Maintained at Overweight by BarclaysDow Jones · 2026/11/3
-
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $254Market Newswire · 2026/11/18
-
Cantor Fitzgerald Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Cuts Target Price to $205Market Newswire · 2026/11/17
-
Company notice
Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Greenstreet YvonneSEC · 2026/11/18
-
Rating change
Alnylam Pharmaceuticals Price Target Cut to $380.00/Share From $450.00 by BarclaysDow Jones · 2026/11/3
-
Company notice
Alnylam Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director SCHULMAN AMY WSEC · 2026/11/13
-
Rating change
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $292 to $455Market Newswire · 2026/11/6
-
Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205Benzinga · 2026/11/17
-
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455Market Newswire · 2026/11/7
-
Rating change
Alnylam Pharmaceuticals Cut to Hold From Buy by Truist SecuritiesDow Jones · 2026/11/2
-
Company notice
Alnylam Pharmaceuticals | 8-K: Current reportSEC · 2026/11/5
-
Company notice
Alnylam Pharmaceuticals | 10-Q: Quarterly reportSEC · 2026/10/29
-
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $410Market Newswire · 2026/11/5
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Alnylam Pharmaceuticals discussion 0 comments